Wednesday, October 01, 2025 11:21:35 PM
Enteric-coated tablets are coated with a polymer coating, often a derivative of cellulose or acrylic acid. The specific coating is chosen based on how and if it breaks down in different pH environments.1
Your stomach is very acidic, with a pH of between 1.5 and 2.0.2 The first part of your small intestine has a pH of around 6, which is much less acidic than your stomach.3
Some medications won't work if they break down in an acidic environment. The purpose of the enteric coating is to protect the medication until it moves into your small intestine. This helps maximize its absorption and increase its effectiveness.
For some medications, the enteric coating also helps protect your stomach from becoming irritated and damaged by the medication itself.
https://www.verywellhealth.com/what-is-enteric-coated-medication-296764#:~:text=Enteric%2Dcoated%20tablets%20are%20coated,damaged%20by%20the%20medication%20itself.
Good luck and GOD bless,
Your stomach is very acidic, with a pH of between 1.5 and 2.0.2 The first part of your small intestine has a pH of around 6, which is much less acidic than your stomach.3
Some medications won't work if they break down in an acidic environment. The purpose of the enteric coating is to protect the medication until it moves into your small intestine. This helps maximize its absorption and increase its effectiveness.
For some medications, the enteric coating also helps protect your stomach from becoming irritated and damaged by the medication itself.
https://www.verywellhealth.com/what-is-enteric-coated-medication-296764#:~:text=Enteric%2Dcoated%20tablets%20are%20coated,damaged%20by%20the%20medication%20itself.
Good luck and GOD bless,
Bullish
Recent VKTX News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:21:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 01:50:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 08:05:17 PM
- Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/29/2026 08:05:00 PM
- Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 • PR Newswire (US) • 04/22/2026 08:35:00 PM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 04/10/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:15:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:14:56 PM
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 • PR Newswire (US) • 03/26/2026 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 03/05/2026 09:03:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (Canada) • 02/13/2026 04:26:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (US) • 02/13/2026 04:26:00 PM
- Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3 • IH Market News • 02/12/2026 02:48:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 10:25:49 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/11/2026 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:06:25 PM
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 • PR Newswire (US) • 02/04/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:57:19 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:55:53 AM
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity • PR Newswire (US) • 01/12/2026 12:00:00 PM
- Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity • PR Newswire (US) • 01/08/2026 12:00:00 PM
- Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer • PR Newswire (US) • 01/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 01:31:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 01:28:24 AM
